Summary in Plain Language
The most dramatic turnaround in the pharmaceutical industry recently wasn’t what everyone initially thought: a win for one company and a loss for another within just 9 days in the mRNA cancer therapy field. In August 2026, Moderna announced the successful results of its first Phase III clinical trial for an mRNA cancer vaccine, causing its stock price to soar to a record high. Nine days later, BioNTech’s similar trial failed, leading to a 8.4% drop in its stock price. At first, it seemed like the two competitors in the COVID-19 vaccine market were determining which one was superior. However, upon closer inspection, it became clear that these two companies, which had become giants thanks to COVID-19 vaccines and reaped billions in profits, had completely opposite goals from the very beginning of their ventures. After the pandemic, they ended up pursuing the very same strategies their rivals had initially adopted, inadvertently damaging the entire mRNA cancer therapy industry. There are no absolute winners or losers; after more than a decade of effort, the industry has finally understood the correct way to utilize mRNA technology.
---
Detailed Analysis
1. The “one success and one failure” within those 9 days were not due to technical differences, but rather to different approaches
Many people assumed that Moderna’s mRNA technology was superior to BioNTech’s. In reality, the core technologies of both companies were almost identical: they used the same nucleoside modification, the same lipid nanoparticle delivery system, and the induced anti-cancer immune cells had similar survival times. The difference lay in their strategies. BioNTech made a fundamental mistake by testing its vaccine on its own to treat colorectal cancer, a type of tumor that the immune system has difficulty detecting. Moreover, they didn’t use the commonly used PD-1 therapy to boost the immune response, which was like sending soldiers to battle without weapons. Moderna, on the other hand, combined its mRNA vaccine with the PD-1 drug Keytruda from the very beginning and chose melanoma, a type of tumor that attracts immune cells naturally. The results from Moderna’s trial were comparable to those of BioNTech’s earlier, smaller-scale studies. In other words, it wasn’t a matter of technical superiority; one company simply took a more straightforward approach from the start.
2. The two companies had completely opposite visions from the very beginning
The reason for their different paths lies in their founding backgrounds. BioNTech was founded by a Turkish-born doctor and scientist couple who saw many cancer patients in the hospital and were determined to create personalized vaccines for each patient, using mRNA as a tool to achieve this goal. Despite skepticism from the scientific community, they persisted and even brought in the Nobel Prize-winning mRNA pioneer Karthikeyan to their team. Moderna, on the other hand, was a company funded by investors with the goal of creating a versatile mRNA platform that could produce multiple drugs for various diseases. Their approaches were as different as climbing up a mountain from different sides.
3. After reaping the benefits of the pandemic, both companies ended up following their rivals’ paths
The pandemic brought massive profits to both companies. Moderna earned $18 billion annually at its peak, while BioNTech’s net profit in 2021 exceeded 10 billion euros. As the pandemic benefits faded, both faced challenges in their respective areas. BioNTech’s focus on personalized mRNA cancer vaccines failed, leading them to shift their strategy and invest billions in buying existing anti-cancer drugs like bispecific antibodies and ADCs. They also hired professional managers from traditional pharmaceutical companies to manage commercialization and outsourced COVID-19 vaccine production to Pfizer to reduce costs. Moderna, after years of promoting its “versatile platform,” finally focused on personalized mRNA vaccines for each patient, significantly reducing the delivery time from 6 weeks to 2 weeks. This shift reflected their initial goals.
4. After a decade of trial and error, the industry realized that mRNA is not a miracle drug, but a tool
The industry had long believed that mRNA could work on its own as a miracle cure. The recent failures have shown that mRNA is essentially a temporary code or a programming tool. Its role is to instruct the body’s cells to produce specific substances—antigens for vaccines, proteins for CAR-T therapy, or enzymes needed by the body. The correct approach involves combining mRNA with other therapies (such as PD-1 and ADCs) to maximize effectiveness. The future of this field will depend on efficiency: how quickly companies can produce and deliver personalized vaccines. If patients have to wait too long, even the best vaccines will be ineffective. Moderna’s investment in specialized factories aims to improve delivery times, which is the real competitive advantage in this field.
In summary, the so-called “reversal” was actually a result of both companies adopting the right strategies after years of trial and error. They both ended up where they initially intended to go, but in opposite directions. There are no absolute winners or losers; the industry has learned that mRNA is a tool to be used in conjunction with other therapies.